Anti-vascular endothelial growth factor for unilateral acute idiopathic maculopathy. Issue 2 (March 2018)

• Record Type: Journal Article
• Authors: Mylonas, Georgios; Prager, Franz; Wetzel, Barbara; Malamos, Panagiotis; Deak, Gabor; Amon, Michael
• Is Part Of: European journal of ophthalmology. Volume 28:Issue 2(2018)
• Page Start: 256
• Page End: 258
• Publication Date: 2018-03
• Subjects: Aflibercept -- Anti-vascular endothelial growth factor -- Unilateral acute idiopathic maculopathy; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; 617.7005
• DOI: 10.5301/ejo.5001070
• Languages: English
• ISSNs: 1120-6721

Abstract

Purpose: To describe a case of unilateral acute idiopathic maculopathy (UAIM) response to intravitreal therapy with aflibercept (Eylea). Methods: Retrospective case report. Results: A 36-year-old woman with sudden visual impairment and central scotoma was found to have a UAIM in her left eye. Three weeks after continuous worsening of her visual acuity and central scotoma, the patient was treated with intravitreal injections of aflibercept. The visual acuity increased and the macula lesion regressed, causing macula scarring after 2 injections. Conclusions: Intravitreal injections of aflibercept could be a therapy option in patients with UAIM without signs of spontaneous resolution of the clinical manifestations and visual improvement.